NCT01213758

Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT

Radiation Induced Change of Liver Function Measured by Uptake of the Galactose Analogue FDGal and PET/CT

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 14 (actual)
• Sponsor: University of Aarhus · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Patients treated with stereotactic radiotherapy for liver tumors undergo PET/CT using the galactose analogue 18-F-deoxy-galactose (FDGal) before and after radiotherapy. This technique provides volumetric mapping of liver function and it allows quantisation of liver function. The method may be used for selection of patients for stereotactic radiotherapy of liver tumors, for determination of radiation induced liver dysfunction and may be included into the treatment planning process of stereotactic radiotherapy.

Conditions

• Hepatocellular Carcinoma
• Cholangiocarcinoma
• Metastases
• Stereotactic Body Radiotherapy

Interventions

Type	Name	Description
OTHER	Measuring liver function by PET/CT	Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors

Timeline

• Start date: 2010-06-01
• Primary completion: 2016-04-01
• Completion: 2016-04-01
• First posted: 2010-10-04
• Last updated: 2017-10-30

Locations

1 site across 1 country: Denmark